Osmotica Pharmaceuticals plc Reports First Quarter 2019 Financial Results and Highlights Pipeline and Business Progress
First quarter 2019 total revenue of $57.1 million; net loss of $6.2 million Positive topline results from second Phase III clinical trials of RVL-1201 for ptosis or droopy eyelid BRIDGEWATER, N.J., May 09, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals …